# Call for Technology Development Projects (TDPs) within Pandemic Laboratory Preparedness (PLP) at Clinical Microbiology laboratories

The PLP program in SciLifeLab has decided to identify and support Technology Development Projects with the potential to generate important capabilities within PLP at the major Clinical Microbiology laboratories in Sweden. This will be done *by* ***financially supporting technology development projects related to pandemic research in Clin Micro labs.*** Research and development of analysis methods is needed before and during pandemics and this can be supported financially within the PLP program and by giving access to the SciLifeLab infrastructure and research network. Areas of interest are diagnostics and analyses of infectious diseases, analyses of immune responses during infections and vaccination and studies of resistance development in viruses, bacteria and other infectious agents. The TDP can also involve***education of personnel and support of bioinformatic analyses and data handling.***

Applicants can apply for up to 1 MSEK/year for 1 year (2022/2023) with a potential for further funding 2024. A maximum of 8 TDPs will be supported in this call.

The main applicant has to be employed by the Clinical Microbiology laboratory and associated with a University. The TDP grant is personal for the main applicant.

|  |  |
| --- | --- |
| Name of proposal |  |
| PI Name |  |
| PI Affiliation (Laboratory, University, Department) |  |
| Email address |  |
| Apply for (SEK) |  |

**Application**

The application is a completed application form.

**Evaluation criteria**

All applications will be evaluated by the SciLifeLab management group and external evaluators. Decision of funding will be made by the SciLifeLab board on March 19, 2022.

**Deadline for applications**: Monday February 7, 2022, 18:00 CET.

**Start of funding**: April 1, 2022. Funds available until July 31, 2023.

**Letter of intent** *(Arial, font 10 pt.)*

1. Short summary of the suggested capability, method development, research and education and why that is important in Pandemic Laboratory Preparedness

2. Plans for the year (2022, April 1st to April 1st, 2023) including clear description on how and why the proposal for pandemic preparedness will be established (max 2 pages).

3. Budget for the TDP 2022/2023 and budget justification. Max 1 million SEK total costs.

4. How the proposed capability could be funded in 2024 and beyond and from which sources (max 0.5 page)

5. How FAIR data principles (Findable, Accessible, Interoperable, Reusable) and data sharing are planned (max 0.5 page)

6. Short CV and relevant top publications/patents of the main PI (max 1 page)

7. Short paragraph of the merits of co-PIs and other parties, including e.g. health care, companies, government or SciLifeLab infrastructure and/or data center/portal (max 1 page)

|  |
| --- |
| 1. Short summary of the suggested capability, method development, research and education and why that is important in Pandemic Laboratory Preparedness (max 0.5 page). |
|  |
| 2. Plans for the year (2022, April 1st to April 1st, 2023) including clear description on how and why the proposal for pandemic preparedness will be established (max 2 pages). |
|  |
| 3. Budget for the TDP 2022/2023 and budget justification. Max 1 million SEK total costs.  |
| **COSTS** | **Justification/Comment** |
| Materials and consumables |  |  |
| Salary |  |  |
| Other costs |  |  |
| Over Head |  |  |
| **Costs in TOTAL (SEK)** |  |  |
| **FUNDING** | **Justification/Comment** |
| Applied funding from SciLifeLab |  |  |
| Funding from [other funding body A], if applicable  |  |  |
| Funding from [other funding body B], if applicable |  |  |
| Funding from [other funding body C], if applicable |  |  |
| **Funding in TOTAL (SEK)** |  |  |

|  |
| --- |
| 4. How the proposed capability could be funded in 2024 and beyond and from which sources (max 0.5 page). |
|  |
| 5. How FAIR data principles (Findable, Accessible, Interoperable, Reusable) and data sharing are planned (max 0.5 page). |
|  |

|  |
| --- |
| 6. Short CV and relevant top publications/patents of the main PI (max 1 page) |
|  |

|  |
| --- |
| 7. Short paragraph of the merits of co-PIs and other parties, including e.g. health care, companies, government or SciLifeLab infrastructure and/or data center/portal (max 1 page) |
|  |